Tilray Brands (TLRY) Net Income towards Common Stockholders (2017 - 2026)
Tilray Brands (TLRY) posted Net Income towards Common Stockholders of -$25.2 million for Q1 2026, up 42.01% on a QoQ basis from -$43.5 million in Q4 2025, and up 96.82% year-over-year from -$12.8 million in Q1 2025.
Tilray Brands (TLRY) Net Income towards Common Stockholders (2017 - 2026) Analysis & Trends
Tilray Brands' Net Income towards Common Stockholders history runs 10 years deep, the most recent figure standing at -$25.2 million for Q1 2026.
- Quarterly Net Income towards Common Stockholders rose 96.82% year-over-year to -$25.2 million in Q1 2026, while the trailing twelve-month figure through Feb 2026 was -$1.5 billion (down 72.77% YoY) and the FY2025 annual result came in at -$2.3 billion, down 1559.72% from the prior year.
- Net Income towards Common Stockholders was -$25.2 million for Q1 2026 at Tilray Brands, up from -$43.5 million in the prior quarter.
- Across five years, Net Income towards Common Stockholders topped out at $816.3 million in Q2 2023 and bottomed at -$1.4 billion in Q2 2025.
- A 5-year average of -$190.7 million and a median of -$55.9 million in 2023 frame the typical range for Net Income towards Common Stockholders.
- Peak annual rise in Net Income towards Common Stockholders reached 425.45% in 2023, while the deepest fall reached 2378.71% in 2023.
- Tilray Brands' Net Income towards Common Stockholders stood at -$85.1 million in 2022, then soared by 45.71% to -$46.2 million in 2023, then tumbled by 84.65% to -$85.3 million in 2024, then soared by 48.98% to -$43.5 million in 2025, then surged by 42.01% to -$25.2 million in 2026.
- Business Quant data shows TLRY's Net Income towards Common Stockholders at -$25.2 million in Q1 2026, -$43.5 million in Q4 2025, and $1.5 million in Q3 2025.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Net Income (Qtr) |
|---|---|---|---|---|---|
| 1 | Haleon | 89.28 Bn | 87.42 Bn | - | - |
| 2 | Teva Pharmaceutical Industries | 35.97 Bn | 32.23 Bn | 1.97 Bn | 370.00 Mn |
| 3 | Zoetis | 32.42 Bn | 30.48 Bn | 1.62 Bn | 601.00 Mn |
| 4 | Takeda Pharmaceutical | 27.48 Bn | 23.42 Bn | 4.39 Bn | -2.35 Bn |
| 5 | United Therapeutics | 22.89 Bn | 20.73 Bn | 648.10 Mn | 274.90 Mn |
| 6 | RedHill Biopharma | 22.11 Bn | 22.11 Bn | - | - |
| 7 | Viatris | 20.44 Bn | 18.64 Bn | 1.16 Bn | 176.40 Mn |
| 8 | Neurocrine Biosciences | 17.76 Bn | 16.44 Bn | 800.70 Mn | 197.90 Mn |
| 9 | Elanco Animal Health | 12.62 Bn | 12.19 Bn | 785.00 Mn | 57.00 Mn |
| 10 | Tilray Brands | 454.65 Mn | 394.45 Mn | 54.95 Mn | -25.23 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Feb 28, 2026 | -25.23 Mn |
| Nov 30, 2025 | -43.51 Mn |
| Aug 31, 2025 | 1.51 Mn |
| May 31, 2025 | -1.39 Bn |
| Feb 28, 2025 | -793.53 Mn |
| Nov 30, 2024 | -85.28 Mn |
| Aug 31, 2024 | -34.65 Mn |
| May 31, 2024 | 68.04 Mn |
| Feb 29, 2024 | -104.98 Mn |
| Nov 30, 2023 | -46.18 Mn |
| Aug 31, 2023 | -55.86 Mn |
| May 31, 2023 | 816.31 Mn |
| Feb 28, 2023 | -1.20 Bn |
| Nov 30, 2022 | -85.06 Mn |
| Aug 31, 2022 | -65.79 Mn |
| May 31, 2022 | -250.82 Mn |
| Feb 28, 2022 | 52.48 Mn |
| Nov 30, 2021 | 5.80 Mn |
| Aug 31, 2021 | -34.60 Mn |
| May 31, 2021 | 345.90 Mn |